ZS Associates is a consulting and analytics firm whose center of gravity is life-sciences commercial: sales-force design, targeting, promotion response, forecasting, and related medtech work. Interviews are quantitative and industry-specific. ZS publishes practice cases that wander into airlines or CPG; do not let that trick you into prepping only generalist MBB. The live job, for most campus consulting seats, still sounds like pharma math.
This CoachNed guide is independent and not affiliated with ZS. Office and role (consulting vs data science vs intern) change the mix. Confirm recruiting. Pay must be confirmed with recruiting.
Last full pass: 24 August 2026.
Adjacent but different: IQVIA (data + launch + access, different firm), Simon-Kucher (pricing architecture), pharma cases (often MBB-flavored). ZS is the one that will make you size a sales force and talk about response curves.
Interview shape
Commonly: behavioral, a quantitative case (sometimes interviewer-led, sometimes with a packet), sometimes a written or take-home analytics exercise, Super Day with more cases. Data-science tracks add technical depth. ZS cases reward clean setup, units (TRx, NRx, calls, reach/frequency), and not overclaiming causality from promotional data.
A CoachNed case is a reasonable gym for driving and math if you pick healthcare-flavored prompts and debrief in commercial-analytics language. It is not a substitute for knowing what a call plan is.
Worked example: specialty-drug sales-force sizing (not grocery mix)
Prompt. A biotech will launch a rare-disease therapy with 2,400 US treaters who ever see the condition. Current plan: 80 reps, 8 calls per day, 220 workdays, targeting the top 1,200 physicians. Should they hire 80, 50, or 110?
Clarify. Success is year-1 new-patient starts net of cost, not “share of voice” as a vanity metric. You may use a contract sales org. Frequency caps and access (some offices refuse reps) are in-scope.
Structure (commercial analytics, not 3C).
- Universe: treaters vs true writers vs “never see this disease”
- Response: starts as a function of reach/frequency, with diminishing returns
- Access: vacant territories, no-see rates
- Cost: fully loaded rep vs expected value of an incremental start
- Mix: MSL vs sales vs digital (do not double-count)
Math (illustrative). Capacity: 80 × 8 × 220 = 140,800 calls/year. If 18% of planned calls are wasted on no-see or leftover frequency on loyalists, productive calls ≈ 115,000. Top 1,200 targets × 12 calls/year would need 14,400 calls if fully covered; you have capacity to cover them and still spill into the next tier. The decision is not capacity; it is response.
Suppose a simple diminishing curve you state out loud: going from 0 to 8 calls/year on a high-decile writer lifts expected starts from 0.4 to 1.1 (+0.7); 8 to 16 lifts +0.15 more. Extra 30 reps (43,000 productive calls) mostly buy frequency on already-covered high deciles → maybe +40 starts. Therapy net price $180k/year, gross-to-net 35% off so net $117k, contribution after COGS 80% → **$94k contribution per start-year**. Forty starts × $94k = $3.8m. Thirty reps at $280k fully loaded = $8.4m. The 110-rep plan destroys value in year 1.
Fifty reps: you cut the long tail, keep high-decile frequency, save 30 × $280k = $8.4m, and lose maybe 25 tail starts × $94k = $2.4m. 50 is better than 80 on this toy model, with the risk that competitive launches need presence.
Recommendation. Do not hire 110. Prefer ~50–60 with a tighter target list and a digital/MSL plan for the tail. Risk: the response curve was built on a different therapy class. Next step: analog brands’ reach-frequency tables, not a generic “more share of voice.”
What a McKinsey-trained candidate does wrong here
They build a market-entry or 3C. They maximize number of reps as “commitment.” They ignore diminishing returns. They treat TRx as revenue. They never say gross-to-net. They recommend a 5% price cut. They cannot define a target list.
ZS interviewers live in these models. They hire people who will not linear-extrapolate a response curve.
How to prepare
- Vocabulary: TRx/NRx, call plan, reach/frequency, analog, gross-to-net, specialty pharmacy, access.
- Practice diminishing returns math and stating the analog assumption.
- Drill case math.
- Behavioral: messy data, changing a model when the first specification was wrong (econ-consulting honesty helps here too).
Frequently asked questions
Official ZS material?
No. Independent. Confirm format and pay with recruiting. Use ZS’s own published practice cases as a supplement, not as a promise your prompt will be an airline.
Do I need a PhD?
No for many consulting roles. Data science is a different bar.
Is it candidate-led?
Often you still need to drive the quantitative story. Do not wait for exhibits if they expect you to ask.
Next step
Rebuild the 50 vs 80 vs 110 comparison with your own response-curve assumptions, and name what analog would change the call. That habit is the interview.
CoachNed is independent and unaffiliated with ZS Associates, McKinsey, BCG, Bain, or other firms named for interview-style practice. Cases on CoachNed are AI-simulated.